• Venn Therapeutics on Twitter
  • Venn Therapeutics on LinkedIn

©2017 BY VENN THERAPEUTICS LLC.

Tampa, FL, USA

Venn in the News

April 23, 2018

Venn Therapeutics acquires a novel integrin αvβ8 antibody precisely targeting TGF-β for cancer immunotherapy

Venn Therapeutics has completed an exclusive licensing deal with the University of California, San Francisco (UCSF) to advance its novel integrin αvβ8 antibody, created by a team of preeminent scientists at UCSF, led by Dr. Stephen Nishimura.

January 21, 2018

Dr. Stefani Spranger Joins Venn Therapeutics’ Scientific Advisory Board

Venn Therapeutics, a privately held immuno-oncology company focused on developing novel, early-stage cancer therapies, announced today that Dr. Stefani Spranger, Assistant Professor, Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, has been appointed to its scientific advisory board.

October 18, 2017

Venn Therapeutics Welcomes Joseph Lobacki to Its Board of Directors

Venn Therapeutics announced today that Mr. Joseph Lobacki has been appointed to its board of directors. Mr. Lobacki has 30 plus years of experience working within the pharma and biotech industry, which have been marked by an impressive history of success and delivering significant shareholder value.

October 09, 2017

Venn Therapeutics Hires Head of Medicinal Chemistry

Venn Therapeutics announces the hiring of Dr. Jim Leahy as the Head of Medicinal Chemistry. Dr. Leahy previously spent 14 years at Exelixis as the Senior Director of Chemistry. While there, he oversaw the discovery of more than a dozen compounds that entered clinical trials. To date, his work has resulted in 3 FDA approved cancer drugs as well as many candidates that are still in late stage clinical trials.

June 02, 2017

Venn Therapeutics Presents at 2017 Sachs Immuno-Oncology BDLI Forum:

Venn Therapeutics' CEO, Sam Shrivastava, presents to attendees as the Sachs 3rd Annual IOBDLI Forum in Chicago. The presentation features an overview of Venn's approach, technologies, and on-going development. 

May 25, 2017

Venn Therapeutics acquires a novel β-catenin/BCL9 Inhibitor to turn “Cold” tumors “Hot”

The University of Utah Research Foundation has partnered with Venn Therapeutics, a biotechnology company focused on developing immune priming oncology therapies, to advance its novel small molecule β-catenin/BCL9 inhibitor, invented by Dr. Haitao (Mark) Ji.

April 05, 2017

Promising New Cancer Therapy developed via Michigan State University and Venn Therapeutics Partnership

Michigan State University (MSU) researchers presented promising cancer therapy results at the American Association for Cancer Research (AACR) International Meeting in Washington, DC. This novel technology, AdVCA0848, activates the stimulator of interferon genes (STING) pathway to delay tumor growth in a B16 melanoma model, promoting beneficial anti-tumor responses.

January 04, 2017

The USF Tampa Bay Technology Incubator Welcomes Venn Therapeutics

Venn Therapeutics, a biotechnology company focused on developing immuno-oncology therapies, has recently joined the University of South Florida’s Tampa Bay Technology Incubator (TBTI). 

Please reload